Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,301
datasets available to search
ShareScore release 0.9.0
Dataset results
1,301 results for “Retrospective Studies”
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
ClinicalTrials.gov study NCT03327571. IPD Sharing: YES. Countries: 1. Publications: 2.
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: retrospective cohort study
<p><strong>Abstract</strong></p> <p><strong>Background</strong>: Extensively drug-resistant tuberculosis (XDR TB) is a very serious form of tuberculosis that is burdened with a heavy mortality toll, especially before the advent of new TB drugs. The Democratic Republic of the Congo (DRC) is among the countries most affected by this new epidemic.</p> <p><strong>Methods:</strong> A retrospective analysis was performed of the records of all patients with pre- and extensively drug-resistant tuberculosis hospitalized from January 1, 2015 to December 31, 2017 and monitored for at least 6 months to one year after the end of their treatment in Kinshasa; an individualized therapeutic regimen with bedaquiline for 20 months was built for each patient. The adverse effects were systematically monitored.</p> <p><strong>Results:</strong> Of the 40 laboratory-confirmed patients, 32 (80%) patients started treatment, including 29 preXRB and 3 XDR TB patients. In the eligible group, 3 patients (9.4%) had HIV-TB coinfections. The therapeutic success rate was 53.2%, and the mortality rate was 46.8% (15/32); there were no relapses, failures or losses to follow-up. All coinfected HIV–TB patients died during treatment. The cumulative patient survival rate was 62.5% at 3 months, 53.1% at 6 months and 53.1% at 20 months. The most common adverse events were vomiting, Skin rash, anemia and peripheral neuropathy.</p> <p><strong>Conclusion: </strong>Bedaquiline based treatment improves patient survival in the DRC despite the still high mortality rate. The new anti-tuberculosis<br> drugs are a real hope for the management of Drug Resistant tuberculosis patient and other new therapeutic combinations may improve favorable outcomes.</p>
Data from: One and two year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource
Objectives: To analyse treatment outcomes and share clinical data from a large, single-center, well-curated database (8174 eyes / 6664 patients with 120,756 single entries) of patients with neovascular age related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (VEGF). By making our depersonalised raw data openly available, we aim to stimulate further research in AMD, as well as setting a precedent for future work in this area. Setting: Retrospective, comparative, non-randomised electronic medical record (EMR) database cohort study of the UK Moorfields AMD database with data extracted between 2008 and 2018. Participants: Including one eye per patient, 3357 eyes/patients (61% female). Extraction criteria were ≥ 1 ranibizumab or aflibercept injection, entry of "AMD" in the diagnosis field of the EMR, and a minimum of one year of follow-up. Exclusion criteria were unknown date of first injection and treatment outside of routine clinical care at Moorfields before the first recorded injection in the database. Main outcome measures: Primary outcome measure was change in VA at one and two years from baseline as measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Secondary outcomes were the number of injections and predictive factors for VA gain. Results: Mean VA gain at one-year and two years were +5.5 (95%CI:5.0,6.0) and +4.9 (95%CI:4.2,5.6) letters respectively. Fifty-four percent of eyes gained ≥5 letters at two years, 63% had stable VA (±≤14 letters), forty-four percent of eyes maintained good VA (≥70 letters). Patients received a mean of 7.7 (95%CI:7.6,7.8) injections during year one and 13.0 (95%CI:12.8,13.2) injections over two years. Younger age, lower baseline VA, and more injections were associated with higher VA gain at two years. Conclusion: This study benchmarks high quality EMR study results of real life AMD treatment and promotes open science in clinical AMD research by making the underlying data publicly available.
A comparative assessment of the dentoskeletal effects of clear aligners versus miniplate-supported posterior intrusion with fixed appliances in adult anterior open bite patients. A multi-centre, retrospective cohort study.
<p>In this retrospective study, the aim was to evaluate the dentoskeletal effects of clear aligner treatment (Invisalign®) versus miniplate-supported posterior intrusion (MSPI) in adults with anterior open bite.</p>
Data from: Association between total dose of ritodrine hydrochloride and pulmonary edema in twin pregnancy: a retrospective cohort study in Japan
Objective Pulmonary edema is recognized as a severe side effect of ritodrine hydrochloride. Recently, the number of twin pregnancies has been increasing. Few studies have reported the association between total dose of ritodrine hydrochloride prior to delivery and pulmonary edema in twin pregnancy. We aimed to examine this association and determine the optimal cutoff threshold of total ritodrine hydrochloride dose to predict the incidence of pulmonary edema in twin pregnancy, based on obstetric records. Design Retrospective cohort study. Setting Yamanashi Prefectural Central Hospital, Japan Participants Two hundred twenty-six women with twin pregnancy who delivered at Yamanashi Prefectural Central Hospital between September 2009 and November 2016 Methods The obstetric records of the participants were analyzed. We defined one unit of ritodrine hydrochloride as 72 mg per 24 h continuous transfusion at 50 µg/min to calculate the dose of ritodrine used for tocolysis. Outcome measures Multivariable logistic regression analysis was performed to examine the association between total dose of ritodrine hydrochloride used for threatened preterm labor and pulmonary edema, while controlling for potential confounding factors. Then, a receiver-operating characteristic curve was used to determine the optimal cutoff of total ritodrine dose to predict pulmonary edema incidence. Results Mean maternal age was 32 (range, 18-46) years; 143 participants were nulliparous (63.3%), 109 had (48.2%) term deliveries, and 194 (85.8%) had cesarean deliveries. The overall incidence of pulmonary edema was 13.7% (31/226). Multivariable analysis showed that the total dose of ritodrine was significantly associated with pulmonary edema (adjusted odds ratio 1.02; 95% confidence interval, 1.004-1.03). The best cut-off point to predict the incidence of pulmonary edema was 26 units (1872 mg) (sensitivity, 61.3%; specificity, 87.8%). Conclusion Our results suggest that consideration of the total dose of ritodrine hydrochloride is helpful in the management of patients with threatened preterm labor in twin pregnancy.
Data from: the characteristics and treatment for severe postpartum hemorrhage in different midwifery hospitals in one district of Beijing in China: an institution-based, retrospective cohort study
<p><span><strong>Objective:</strong> </span><span>To identify the characteristics and treatment approaches for Severe Postpartum Hemorrhage (SPPH) patients in various midwifery institutions in one district in Beijing, especially those without identifiable antenatal PPH risk factors, to improve regional SPPH rescue capacity.</span></p> <p><strong><span>Design:</span></strong><span> Retrospective cohort study</span></p> <p><span><strong>Setting:</strong> </span><span>This study was conducted at n</span><span>ine tertiary-level hospitals and ten secondary-level hospitals</span><span> in Haidian district of Beijing from January 2019 to December 2022. </span></p> <p><strong><span>Participants:</span></strong> <span>The major inclusion criterion was SPPH cases with blood loss </span>≥<span>1500 ml or needing a packed blood product transfusion </span>≥<span>1000 ml within 24 h after birth</span><span>.</span><span> A total of 324 mothers suffering from SPPH were reported to the Regional Obstetric Quality Control Office from 19 midwifery hospitals. </span></p> <p><span><strong>Outcome measures:</strong> </span><span>The pregnancy characteristics collected included: age at delivery, gestational weeks at delivery, height, parity, delivery mode, antenatal PPH risks, etiology of PPH, bleeding amount, PPH complications, transfusion amount, and PPH management. SPPH characteristics were compared between two levels of midwifery hospitals and their association with antenatal PPH high-risk factors was determined.</span></p> <p><span><strong>Results:</strong> </span><span>SPPH was observed in 324 mothers out of 106697 mothers in the four years. There were 74.4% and 23.9% cases of SPPH without detectable antenatal PPH high-risk factors in secondary and tertiary midwifery hospitals, respectively. Primary uterine atony was the leading cause of SPPH in secondary midwifery hospitals, whereas placental-associated disorders were the leading causes in tertiary institutions, accounting for over 50% of cases. In all SPPH cases, the rates of red blood cell transfusion over 10U, </span><span>unscheduled returns to the operating room,</span><span> and adverse PPH complications were higher in patients without antenatal PPH risk factors. Secondary hospitals had significantly higher rates of trauma compared with tertiary institutions.</span></p> <p><span><strong>Conclusion:</strong> </span><span>Examining SPPH cases at various institutional levels offers a more comprehensive view of regional SPPH management and enhances targeted training in this area.</span></p>
Quality of life in chronic pain treated through pulsed radiofrequency therapy: A retrospective study
<p>Anxiety and depression are often symptoms present in people who suffer from chronic pain, compromising the quality of life of these individuals. The objective of this study was to assess whether a pulsed radiofrequency (PRF) treatment, in addition to psychological support intervention, can decrease chronic pain, thereby improving quality of life and restoring psychological well-being.Fifty outpatients with a diagnosis of chronic pain, without any benefit from traditional drug therapies, were selected to perform a PRF treatment in combination with a psychological intervention. They were evaluated before and after the intervention through the Hamilton Anxiety Rating Scale and the Beck Depression Inventory-II for anxiety and depression symptomatology, respectively, the Short Form Health Survey 36 (SF-36) was used to assess the subject's quality of life, and the Numerical Rating Scale was used for pain assessment.The Wilcoxon signed-rank test showed a significant difference in Beck Depression Inventory-II (P < .001), Hamilton Anxiety Rating Scale (P < .01), and Numerical Rating Scale (P = .004). In the SF-36 scores, we observed a significant difference between T0 and T1 in both mental (P < .001) and physical (P < .001) dimensions.This study shows that a chronic pain reduction leads to a decrease of anxiety-depressive symptoms and an improvement in quality of life. PRF seems to be an appropriate method to reduce the chronic pain that influences psychological well-being and quality of life.</p>
Comparison of the Birth Weights of Infants with Esophageal Atresia and Tracheoesophageal Fistula and Infants with Inguinal Hernia: A Retrospective Case–Control Study
<p>Esophageal atresia with tracheoesophageal fistula is the most common tracheoesophageal malformation. Amniotic fluid swallowing into the upper blind sack and aspiration were observed during fetal life. Tracheoesophageal fistula serves as a sideway passage of amniotic fluid into the gastrointestinal tract. Compared with inguinal hernia, gestational age adjusted birth weights were lower for infants with esophageal atresia. In esophageal atresia with tracheoesophageal fistula nutrition by aspirated amniotic fluid did not fully compensate the intrauterine growth deficit.</p>
Kidney transplantation waiting times and risk of cardiovascular events and mortality: a retrospective observational cohort study in Taiwan
<p>Objectives: Patients with end-stage renal disease (ESRD) are at a high risk of cardiovascular events (CVEs), and kidney transplantation (KT) has been reported to improve risk of CVEs and survival. As the association of KT timing on long-term survival and clinical outcomes remains unclear, we investigated the association of different KT waiting times on clinical outcomes.</p> <p>Design: Retrospective observational cohort study.</p> <p>Setting: We conducted an observational cohort study using data from the National Health Insurance Research Database in Taiwan. Adult patients who initiated kidney transplantation therapy from 1997 to 2013 were included.</p> <p>Participants: A total of 3562 adult patients who initiated uncomplicated KT therapy were included and categorized into four groups according to KT waiting times after ESRD: Group 1 (<1 year), Group 2 (1–3 years), Group 3 (3–6 years), and Group 4 (>6 years).</p> <p>Primary outcome measure: The main outcome was a composite of all-cause death, nonfatal myocardial infarction, or nonfatal stroke, based on the primary diagnosis in medical records during hospitalization.</p> <p>Results: Compared with Group 1, the adjusted risk of primary outcome events (all-cause death, nonfatal myocardial infarction, or nonfatal stroke) increased by 1.67 times in Group 2 (95% CI: 1.40–2.00; P <0.001), 2.17 times in Group 3 (95% CI: 1.73–2.71; P <0.001), and 3.10 times in Group 4 (95% CI: 2.21–4.35; P <0.001). The rates of primary outcome events were 6.7%, 13.4%, and 14.0% within five years, increasing to 19.5%, 26.3%, and 30.8% within 10 years in Groups 1, 2, and 3, respectively.</p> <p>Conclusions: Our results demonstrate that early KT is associated with superior long-term cardiovascular outcomes compared to late KT in selected ESRD patients receiving uncomplicated KT, suggesting that an early KT could be a better treatment option for ESRD patients who are eligible for transplantation.</p>
An ordinal severity scale for COVID-19 retrospective studies using electronic health record data
<p><span>Objectives: </span><span>Although the World Health Organization (WHO) Clinical Progression Scale for COVID-19 is useful in prospective clinical trials, it cannot be effectively used with retrospective Electronic Health Record (EHR) datasets. Modifying the existing WHO Clinical Progression Scale, we developed an ordinal severity scale (OS) and assessed its usefulness in the analyses of COVID-19 patient outcomes using retrospective EHR data.</span></p> <p><span>Results: </span><span>The data set used in this analysis consists of 2,880,456</span> <span>patients</span><span>. PCA of the day-to-day variation in OS levels over the totality of the 28-day</span> <span>period revealed contrasting patterns of variation in disease severity within the first and second 14 days and illustrated the importance of evaluation over the full 28-day period.</span></p> <p><span>Discussion:</span><span> An OS with well-defined, robust </span><span>features, based on discrete EHR data elements, is </span><span>useful for assessments of COVID-19 patient outcomes, providing insights on progression of COVID-19 disease severity over time.</span></p> <p><span>Conclusion</span><span>: The </span><span>OS </span><span>provides a framework which can facilitate better understanding of the course of acute COVID-19, informing clinical decision-making and resource allocation.</span></p>
"Abdominal pain in emergency departments in a well-developed primary care system, a retrospective observational study"
<p>This is the dataset that is used for the original article:</p> <p>“Abdominal pain in emergency departments in a well-developed primary care system, a retrospective observational study”</p>
Deciphering the explanatory potential of blood pressure variables on post-operative length of stay through hierarchical clustering: A retrospective monocentric study
<p><em>Objective:</em> Mean arterial pressure is widely used as the variable to monitor during anesthesia. But there are many other variables proposed to define intraoperative arterial hypotension. The goal of the present study was to search arterial pressure variables linked with prolonged postoperative length of stay (pLOS).</p> <p><em>Design: </em>Retrospective cohort study of adult patients having received general for a scheduled non cardiac surgical procedure between 15<sup>th</sup> July 2017 and 31st December 2019.</p> <p><em>Methods:</em> pLOS was defined as a stay longer than the median (main outcome), adjusted for surgery type and duration. 330 arterial pressure variables were analyzed and organized through a clustering approach. An unsupervised hierarchical aggregation method for optimal cluster determination, employing Kendall's tau coefficients and a penalized Bayes information criterion was used. Variables were ranked using the absolute standardized mean distance (aSMD) to measure their effect on pLOS. Finally, after multivariate independence analysis, the number of variables was reduced to three.</p> <p><em>Results:</em> Our study examined 9,516 patients. When LOS is defined as strictly greater than the median, 34% of patients experienced pLOS. Key arterial pressure variables linked with this definition of pLOS included the difference between the highest and lowest pulse pressure values computed throughout the surgery (aSMD[95%CI] =0.39[0.31-0.40], p<0.001), the accumulated time pulse pressure above 61mmHg (aSMD = 0.21[0.17-0.25], p<0.001), and the lowest MAP during surgery (aSMD= 0.20[0.16-0.24], p<0.001).</p> <p><em>Conclusions: </em>By applying a clustering approach, three arterial pressure variables were associated with pLOS. This scalable method can be applied to various dichotomized outcomes.</p>
Fig. 1 in A retrospective epidemiological study of sarcoptic mange in koalas (Phascolarctos cinereus) using wildlife carer admission records
Fig. 1. Map of locations of koalas (Phascolarctos cinereus) admitted with sarcoptic mange.
Breaking the ice to improve motor outcomes in patients with chronic stroke: a retrospective clinical study on neuromodulation plus robotics
<p>Stroke is one of the main causes of impairment affecting daily activities and quality of life. There is a growing effort to potentiate the recovery of functional gait and to enable stroke patients to walk independently. To estimate the effects of dual-site transcranial direct current stimulation (dstDCS) on gait recovery in chronic stroke patients provided with robot-aided gait training (RAGT). Thirty-seven patients were included in this retrospective clinical study. Nine patients were provided with dstDCS during the first 10 min of RAGT by using Lokomat®Pro (on-RAGT), 15 patients immediately after RAGT (post-RAGT), and 13 patients immediately before RAGT (pre-RAGT). Each group improved over time concerning disability burden and lower limb strength. on-RAGT and post-RAGT experienced better improvement in balance (p < 0.001) and, moderately, gait endurance (p = 0.04) as compared to pre-RAGT. Furthermore, all treatments decreased the facilitation of the unaffected hemisphere (p < 0.001) and the inhibition of the affected hemisphere (p < 0.001). The duration of such aftereffects was found to be greater for post-RAGT. This is the first trial with dstDCS coupled with RAGT in chronic stroke patients with gait impairment. When timely coupled with RAGT, dstDCS may be considered an effective tool for the recovery of lower limb function in patients with first unilateral stroke in the chronic phase. Moreover, our data suggest the ductility of dstDCS concerning RAGT timing, thus making this intervention suitable in a neurorehabilitation setting and well adaptable to patients’ needs. </p>
Etiology, characteristics and occurrence of heart diseases in rural Lesotho (ECHO-Lesotho): A retrospective echocardiography cohort study
<p><strong>Background</strong></p> <p>In 2019, 600’000 people in Africa died of heart failure and heart diseases will increase on the continent. It is crucial to understand the regional etiologies and risk factors for heart failure and underlying heart diseases. However, echocardiography data from rural Africa are scarce and from Lesotho non-existent. This study aims to examine the occurrence, characteristics and etiology of heart failure and heart diseases using echocardiography data from a referral hospital in rural Lesotho.</p> <p><strong>Methods</strong></p> <p>We conducted a retrospective cohort study at Seboche Mission Hospital, the only referral hospital in Butha-Buthe district (Lesotho) with an echocardiography department. We included data from all individuals referred to the department between January 2020 and May 2021. From non-hospitalized patients echocardiographic diagnosis, sex and age were available, from hospitalized patients additional sociodemographic and clinical data could be extracted.</p> <p><strong>Results</strong></p> <p>In the study period, a total of 352 echocardiograms were conducted; 213 had abnormal findings (among them 3 children). The majority of adult participants (130/210; 64%) were female and most frequent heart diseases were hypertensive (62/210, 30%), valvular (39/210, 19%) and chronic pulmonary (37/210, 18%). Heart failure represented 11% of hospitalizations in the same period. Among the 126 hospitalized heart failure patients, the most common etiology was chronic pulmonary heart disease (32/126; 25%). Former mine workers and people with a history of tuberculosis were more likely to have a chronic pulmonary heart disease.</p> <p><strong>Conclusions</strong></p> <p>The leading cause of heart disease in this setting is hypertension. However, in contrast to other African epidemiological studies, chronic pulmonary heart disease is unexpectedly common. There is an urgent need to improve awareness and knowledge about lung diseases, make diagnostic and therapeutic options available and increase prevention.</p>
Data from: Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson's disease: A retrospective study
<p><span>Patients with Parkinson's disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD.</span></p> <p><span>CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics.</span></p> <p><span>We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7–334.5] pg/mL) were lower than those in controls (352.2 [296.2–399.5] pg/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics.</span></p> <p><span>This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD.</span><span> Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.</span></p>
Positive p53 expression is significantly found higher in luminal B HER-2 negative cases with primary endocrine therapy resistance: A multicenter retrospective cross-sectional study in Indonesia
<p><strong>Positive p53 expression is significantly found higher in luminal B HER-2 negative cases with primary endocrine therapy resistance: A multicenter retrospective cross-sectional study in Indonesia</strong></p>
Industry funding of patient organisations in the United Kingdom: A retrospective study of commercial determinants, funding concentration and disease prevalence
<p><strong>Objectives</strong> – To assess the relationship between UK-based patient organisation funding and companies' commercial interests in rare and non-rare diseases in 2020.</p> <p><strong>Design</strong> – Retrospective analysis of the value and volume of payments from pharmaceutical companies to patient organisations in the UK matched with data on the conditions supported by patient organisations and drugs in companies' approved portfolios and research and development pipelines.</p> <p><strong>Setting</strong> – UK.</p> <p><strong>Participants</strong> – 74 pharmaceutical companies making payments to 341 UK-based patient organisations.</p> <p><strong>Main outcome measures</strong> – Alignment between the commercial interests of pharmaceutical companies and the disease area focus of patient organisations; difference in the volume and value of payments to patient organisations broken down by prevalence of conditions; industry funding concentration, measured as the number of companies funding each patient organisations, the share of overall industry funding coming from each contributing company and the share of industry funding of each organisation comprised by the single highest payments.</p> <p><strong>Results</strong> – 1,422 payments were made by 74 companies to 341 patient organisations. Almost all funds (90%) from pharmaceutical companies were directed to patient organisations that are aligned with companies' approved drug portfolios and research and development pipelines. Despite rare diseases affecting less than 5% of the UK population, more than 20% of all payments were directed to patient organisations which target such conditions. Patient organisations focusing on rare diseases relied on payments from fewer companies (p-value = 0.0031) compared to organisations focusing on non-rare diseases.</p> <p><strong>Conclusions</strong> – Companies predominantly funded patient organisations operating in therapeutic areas relevant to companies' portfolio or drug development pipeline. Patient organisations focusing on rare diseases received more funding relative to the number of patients affected by these conditions and relied more heavily on payments from fewer companies compared to organisations targeting non-rare diseases. Increased independence of patient organisations could help avoiding conflicts of interest.</p>
Clinical expression of programmed maxillary buccal expansion and buccolingual crown inclination with Invisalign® EX30® and SmartTrack® aligners and investigating the effect of 1-week vs 2-week aligner change regimes: A retrospective study.
<p><strong><em>Objective:</em></strong> The objective of this retrospective cohort study is to assess and compare the accuracy of three different Invisalign<sup>® </sup>treatment regimens involving variations of aligner change frequency and type of aligner material in achieving maxillary dental buccal expansion.</p> <p> </p> <p><strong><em>Methods:</em></strong> 120 adult patients whose treatment involved maxillary dental expansion with Invisalign<sup>®</sup> were selected. Three groups, each of 40 patients were identified: SmartTrack<sup>®</sup> one-week changes (ST1), SmartTrack<sup>®</sup> two-week changes (ST2) and EX30<sup>®</sup> two-week changes (EX2). The groups were assessed by comparing actual changes achieved with those prescribed by ClinCheck<sup>®</sup>. The rates of clinically significant inaccuracies (CSI) seen for buccal expansion (≥ 0.5mm) and buccolingual inclination (≥2°) during expansion were then ascertained.</p> <p> </p> <p><strong><em>Results:</em></strong> With respect to expansion, the ST1 group showed the highest rate of CSI at all tooth levels studied while the ST2 group showed the lowest rate of CSI as well as the lowest mean inaccuracy for each tooth level studied. In terms of buccolingual inclination, the ST1 group displayed the highest rate of CSI across all tooth levels studied, while the EX2 group displayed the lowest rate of CSI at all tooth levels except for the canine level where the ST2 group displayed the lowest rate of CSI. A tendency toward overexpression of buccal crown inclination, and underexpression of buccal expansion was seen at all tooth levels.</p> <p> </p> <p><strong><em>Conclusions:</em></strong> Two-week aligner change regimens offer improved accuracy compared with one-week aligner changes. SmartTrack<sup>®</sup> two-week changes were the most accurate for buccal expansion, while EX30<sup>®</sup> 2-week changes were the most accurate for buccolingual inclination.</p>
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in Southeastern China
<p class="MsoNormal"><span>Objective: To evaluate the associations between serum uric acid (SUA) levels and cardiovascular disease (CVDs) risk factors, focusing on potential sex-specific differences.</span></p> <p class="MsoNormal"><span>Design: A retrospective cohort study.</span></p> <p class="MsoNormal"><span>Setting: A large community-based survey was conducted every two years from 2010 to 2018 in Hangzhou, Zhejiang Province, Southeastern China.</span></p> <p class="MsoNormal"><span>Participants: 6119 participants aged 40 years and above who underwent at least three times of physical examinations were enrolled. </span></p> <p class="MsoNormal"><span>Methods: Participants were categorized into four groups (Q1-Q4) based on baseline SUA quartiles within the normal range, with hyperuricemia (HUA) as the fifth group. The Q1 was the reference. By stratifying participants by gender, the relationships between SUA levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and total cholesterol (TC) were investigated using linear regression models in the generalized estimating equation (GEE). Additionally, the associations of elevated SUA levels and HUA with hypertension, hyperglycemia, and dyslipidemia were correspondingly examined using multivariate logistic regression models.</span></p> <p class="MsoNormal"><span>Results: After adjusting for confounding variables, we found positive associations between SUA levels and SBP, DBP, FBG, and TC in women, and with TC in men (P < 0.01). Likewise, Elevated SUA quartiles and HUA were linked to increased dyslipidemia risk in both sexes, and increased hyperglycemia risk only in women, with HRs (95%CI) of 1.64 (1.05-2.55) and 2.37 (1.47-3.81) in the Q4 and HUA group, respectively. Women with HUA had higher hypertension risk (HR=1.45, 95% CI 1.21-1.73), while no such association was observed in men. Stratified analyses revealed significant associations between elevated SUA levels and CVDs risk factors in postmenopausal and non-obese women.</span></p> <p class="MsoNormal"><span>Conclusions: Elevated SUA levels increase the risk of dyslipidemia in both sexes. SUA levels within normal-range and HUA are positively associated with hyperglycemia and hypertension in postmenopausal women, but not in men.</span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.